Skip to content

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

PUBLICATIONS and presentations

Explore our research and learn more about the science backing our approach.

Year
Search

June 27, 2025 | Molecular Therapy

Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation

May 11, 2024 | 27th ASGCT Annual Meeting 2024

Rational Design of a Detargeted Vesiculovirus Fusogen to Enable Targeted In Vivo Gene Delivery

May 11, 2024 | 27th ASGCT Annual Meeting 2024

In Vivo Generation of Both CAR T Cells and CAR NK Cells Using a CD7 Targeted Lentiviral Vector

May 11, 2024 | 27th ASGCT Annual Meeting 2024

In Vivo Delivery of an Engineered Lentiviral CAR19 Vector for the Treatment of Autoimmune Diseases

May 11, 2024 | 27th ASGCT Annual Meeting 2024

Evaluation of Residual Host Cell DNA Clearance and Sizing During Production of a Lentiviral Vector

May 11, 2024 | 27th ASGCT Annual Meeting 2024

Automating a Lentivirus Infectious Titer Assay (ITA)

12

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Science

Platform
Pipeline
INT2104
INT2106
Publications
Clinical Trials

Company

About Us
Leadership
Board of Directors
Careers
Contact
News

Copyright © 2025 Interius BioTherapeutics, Inc. All Rights Reserved.
Interius^® is a registered trademark of Interius BioTherapeutics, Inc.

Accessibility
Cookies Notice
Privacy Notice
Terms of Use

Interius is now part of Kite, a Gilead Company.

We are singularly focused on achieving cures with cell therapy.

Learn More About Kite